EUVIMEDEUVIMED entdecken
Editorial

The 10 Commandments of Transcarotid Transcatheter Aortic Valve Replacement

Keith B Allen, Adnan K Chhatriwalla

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery · 2023-05 · 18 (3) · 217-222

DOI: 10.1177/15569845231174022 ↗

Kurz gefasst

Editorial in der Zeitschrift Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, online erschienen am 06.06.2023. Verfasst von Keith B Allen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, St. Luke's Hospital, St. Luke's Mid America Heart Institute, Kansas City, MO, USA. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transcatheter aortic valve replacement (TAVR) is the dominant technique for treating severe aortic stenosis across a broad range of patients regardless of surgical risk.1–6 While transfemoral access dominates, the ability of the heart team to offer a nonfemoral alterative when iliofemoral access is prohibitive is relevant despite ongoing improvements in transcatheter heart valve (THV) size and deliverability.7–9 Transthoracic access such as transapical (TA) and transaortic predominated early in the evolution of TAVR.10,11 However, as THV technology has improved, less invasive, nonthoracic access options such as subclavian,12,13 axillary,14,15 carotid,7,8,16–21 and transcaval22,23 were increasingly preferred by experienced heart teams. Both transcarotid (TC) and transaxillary (TAx) access have demonstrated superiority over transthoracic access,7,9,24,25 with TAx access emerging early as the favored nonfemoral alternate access based on success in the CoreValve (Medtronic, Dublin, Ireland) THV Pivotal Trials.26,27 While positive outcomes from single centers using TC access have elevated it to the preferred nonfemoral access site of choice at many centers,7,8 robust multicenter comparisons between TC and TAx have been lacking until recently. Two well-matched propensity score studies comparing TC to TAx access using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, 1 study with CoreValve,16 and 1 study with SAPIEN (Edwards Lifesciences, Irvine, CA, USA)8 demonstrated some distinct clinical and procedural advantages of TC compared to TAx access. TC compared to TAx access using a CoreValve16 was associated with a significantly lower rate of stroke at 30 days (Kaplan–Meier rates, 3.1% vs 5.9%, P = 0.017) and 1 year (3.4% vs 7.2%, P = 0.003). Although 30-day mortality was similar (TC 3.7% vs TAx 4.3%, P = 0.57), the composite endpoint of mortality or stroke at 30 days favored TC access (TC 6.0% vs TAx 8.9%, P = 0.033). In addition, TAx access was a strong multivariable predictor for stroke (hazard ratio [HR] = 2.14, 95% confidence interval [CI]: 1.27 to 3.58, P = 0.004) and stroke or death (HR = 1.63, 95% CI: 1.11 to 2.42, P = 0.014) at 30 days. Finally, TC access was associated with a significantly shorter total procedure time (99 vs 118 min, P < 0.001), less fluoroscopy time (P = 0.02), shorter median hospital length of stay (2 vs 3 days, P < 0.001), and a greater likelihood of being discharged directly to home without assistance (88.4% vs 80.7%, P < 0.001). The 5.9% 30-day stroke rate observed in this large propensity-matched study with CoreValve is similar to the 30-day stroke rates of 7.5% and 6.5%, respectively, reported in the CoreValve Extreme Risk U.S. Pivotal Trial27 and in an analysis of patients from the CoreValve Extreme Risk and High Risk Pivotal Trials and Continued Access Study.26 The increased stroke signal with TAx compared to TC access was also observed using the SAPIEN 3 THV in a propensity-matched TVT Registry analysis. Kirker and colleagues demonstrated that TAVR using TC compared to TAx access was associated with similar 30-day mortality (4.3% vs 5.2%, P = 0.34) but a significantly lower risk of stroke (4.2% vs 7.4%, HR = 0.56, 95% CI: 0.38 to 0.83, P = 0.003).8 Similar to CoreValve, TC access using the SAPIEN 3 THV was also associated with a shorter procedure time (117.0 vs 132.4 min, P < 0.001), reduced fluoroscopy time (16.6 vs 21.6 min, P < 0.001), lower contrast volume (78.5 vs 96.7 mL, P < 0.001), shorter hospital stays (2.0 vs 3.0 days, P = 0.002), and increased likelihood of discharge to home (82.9% vs 74.6%, P < 0.001). Although there are no randomized comparisons, improved outcomes associated with TC compared with TAx access are compelling and appear agnostic of THV type, which supports the fact that TC access is currently the most frequently used nonfemoral access site when iliofemoral anatomy is prohibitive.8,16

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisHumansAortic ValveTreatment Outcome

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, St. Luke's Hospital, St. Luke's Mid America Heart Institute, Kansas City, MO, USA.
  • Department of Cardiology, St. Luke's Hospital, St. Luke's Mid America Heart Institute, Kansas City, MO, USA.

Zitieren

APA

Allen, K. B., & Chhatriwalla, A. K. (2023). The 10 Commandments of Transcarotid Transcatheter Aortic Valve Replacement. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 18(3), 217-222. https://doi.org/10.1177/15569845231174022

Vancouver

Allen KB, Chhatriwalla AK. The 10 Commandments of Transcarotid Transcatheter Aortic Valve Replacement. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2023;18(3):217-222. doi:10.1177/15569845231174022

BibTeX
@article{Allen2023,
  author = {Allen, Keith B and Chhatriwalla, Adnan K},
  title = {The 10 Commandments of Transcarotid Transcatheter Aortic Valve Replacement},
  journal = {Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery},
  year = {2023},
  volume = {18},
  number = {3},
  pages = {217--222},
  doi = {10.1177/15569845231174022}
}
Kostenlos starten →